The Accelerated Access Collaborative (AAC) is a unique partnership hosted by NICE bringing industry, government and the NHS together to remove barriers to uptake of innovations, so that NHS patients have faster access to innovations that can transform care.
See the 'Resources' section on the right to find out more about the AAC.
We support the deliver of the AAC's Rapid Uptake Programme (RUP), which has been designed to support stronger adoption and spread of proven innovations. It identifies and supports products with NICE approval that support the NHS Long Term Plan’s key clinical priorities, but have lower than expected uptake to date.
The RUPs we current support comprise;
Lipid Management: High Intensity Statins, Ezetimibe and PCSK9 inhibitors
The Rapid Uptake Product (RUP) for lipid management is a novel, NICE-approved clinical pathway. This innovation aims to improve a person’s lipid profile, by reducing cholesterol concentration in blood by treating patients with the right medicine for them. There are three treatment pathways available: high intensity statins (HIST), ezetimibe, and PCSK9 inhibitors (continued from 2019/20).
Measuring fractional exhaled nitric oxide (FeNO) concentration in asthma: products NIOX VERO and NObreath
FeNO testing is a method that assists with the diagnosis of asthma by measuring fractional exhaled nitric oxide (FeNO) in the breath of patients suspected of having asthma. The aim of this innovation will be to improve patient care and outcomes by more effective diagnosis of patients suspected of having asthma.
Wessex AHSN lead the national FeNO programme and have developed a range of implementation support materials - you can access these on our dedicated FeNO pages (including the national training)
Asthma Biologics for treating severe asthma: Reslizumab, Benralizumab, Mepolizumab and Omalizumab
Asthma Biologics can transform patient lives by reducing asthma attacks, asthma-related hospital admissions and long-term side effects of other treatments such as oral steroids. The aim of this innovation will be to improve patient care and outcomes by improving access to biologics for people with severe asthma. The programme focuses on optimising pathways that help with the early identification of people with uncontrolled asthma, appropriate referral of patients needing further specialist input and supporting patients to self-administer their asthma biologic at home.
